“… - SGLT2 inhibitors can cause euglycemic DKA as a direct effect of their mechanisms of action, noninsulin-dependent glucose clearance, hyperglucagonemia, and volume depletion.
- The recovery phase of DKA may be associated with severe hypophosphatemia requiring timely and appropriate repletion of phosphate ( 9 , 10 ).
- Euglycemic DKA may be overlooked in the setting of moderately elevated blood glucose, which can lead to misdiagnosis, delayed treatment, and worsening metabolic derangements.
…”